Search

Displaying results 1931 - 1940 of 4345 in total
  1. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … [L2506] The product was originally developed by the Scripps Research Institute, then licensed to Windtree Therapeutics.

  2. Drug

    Cocoa butter

    go.drugbank.com/drugs/DB11086
    Approved

    Fat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041 … It is a rich source of monounsaturated and saturated fatty acids [A33040] that mainly contains approximately 33% [DB04224], 25% [DB03796], and 33% [DB03193] [A20409] but does not contain caffeine or theobromine

  3. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control … Although many of them contain several compounds in common (such as the estrogen derivatives sodium estrone sulfate and sodium equilin sulfate), they vary by their original source (such as horse-, human

  4. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

    Products: Urecholine Tab 10mg, Myotonachol Tablets 10mg
  5. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  6. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    It is administered by the intravenous, epidural and sublingual routes. … The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717].

  7. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  8. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred

    Products: METHIZOL SD 20MG, THIAMAZOL 10MG HEXAL
  9. Drug

    Isoprenaline

    go.drugbank.com/drugs/DB01064
    ApprovedInvestigational

    Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, a...

  10. Drug

    Ritiometan

    go.drugbank.com/drugs/DB13267
    Approved

    Ritiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.